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Abstract
BACKGROUND: The clinical utility of echocardiography for the diagnosis of 
pulmonary vascular disease (PVD) in former preterm infants with 
bronchopulmonary dysplasia (BPD) is not established.  Elevated pulmonary 
vascular resistance (PVR) rather than pulmonary artery pressure (PAP) is the 
hallmark of PVD. We evaluated the utility of echocardiography in infants with
BPD in diagnosing pulmonary hypertension and PVD (PVR >3 woods units x 
m2) assessed by cardiac catheterization. 
METHODS: A retrospective single center study of 29 infants born ≤29 weeks 
gestational age with BPD who underwent cardiac catheterization and 
echocardiography was performed. PVD was considered present by 
echocardiography if the tricuspid valve regurgitation jet peak velocity was 
>2.9m/sec, post-tricuspid valve shunt systolic flow velocity estimated a right 
ventricular systolic pressure >35mmHg or systolic septal flattening was 
present. The utility (accuracy, sensitivity and specificity) of 
echocardiography in the diagnosis of PVD was tested. Subgroup analysis in 
patients without post tricuspid valve shunts was performed. 
Echocardiographic estimations of right ventricular pressure, dimensions, 
function and pulmonary flow measurements were  evaluated for correlation 
with PVR.
RESULTS: The duration between echocardiography and cardiac 
catheterization was a median of 1 day (interquartile range: 1 - 4 days). 
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Accuracy, sensitivity and specificity of echocardiography in diagnosing PVD 
were 72%, 90.5% and 25%, respectively. Accuracy, sensitivity and specificity
increased to 93%, 91.7% and 100% when infants with post tricuspid valve 
shunts were excluded. Echocardiography had poor accuracy in estimating 
the degree of PAP elevation by cardiac catheterization. In infants without 
post tricuspid valve shunts, there was moderate-to-good correlation between
indexed PVR and right ventricular myocardial performance index (rho: 0.89, 
p=0.005), systolic to diastolic time index (0.84, p<0.001), right to left 
ventricular diameter ratio at end systole (0.66, p=0.003) and pulmonary 
artery acceleration time (0.48, p=0.05).
CONCLUSIONS: Echocardiography performs well in screening for PVD in 
infants with BPD and may be diagnostic in the absence of a post tricuspid 
valve shunt. However, cardiac catheterization is needed to assess the degree
of pulmonary artery pressure elevation and PVR. The diagnostic utility of 
echocardiographic measurements that correlate with PVR should be 
evaluated prospectively in this patient population.
KEYWORDS:  bronchopulmonary dysplasia, echocardiography, prematurity, 
pulmonary hypertension, pulmonary vascular disease
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ASD: atrial septal defect
BPD: bronchopulmonary dysplasia
CO: cardiac output
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PA: pulmonary artery
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Introduction
The gold standard for diagnosis of pulmonary arterial hypertension due to 
pulmonary vascular disease (PVD) is the cardiac catheterization derived 
calculation of pulmonary vascular resistance (PVR). 1 In former preterm 
infants diagnosed with bronchopulmonary dysplasia (BPD), elevated 
pulmonary artery pressure (PAP) diagnosed by echocardiography is  
associated with substantial risk of mortality.2 Because cardiac catheterization
is an invasive procedure, the American Heart Association 1 and the Pediatric 
Pulmonary Hypertension Network (PPHNet) 3 have recommended performing 
echocardiograms as a less invasive tool to screen for the presence of PVD 
(indicated by elevated PAP) in patients with moderate or severe BPD. 
However, echocardiography does not measure PVR directly but rather uses 
blood flow velocities to estimate pulmonary artery pressure. 4-7 PAP and PVR 
are related to each other through the equation: Pressure = Flow X 
Resistance; thus elevated PVR is inferred by an elevated estimated PAP as 
long as pulmonary blood flow is not considered to be substantially elevated.
Prior studies have assessed the agreement and accuracy of estimated 
PAP by echocardiographic measurement of blood flow velocities and 
simultaneously measured PAP during cardiac catheterization in older children
and young adults. This agreement has been found to be variable, with 
greater discrepancies at higher measured PAP.4,6,7  In younger children, 
Mourani and colleagues showed poor correlation between the PAP estimated 
by echocardiography from tricuspid regurgitant (TR) jet velocity to that 
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measured during cardiac catheterization in infants with chronic lung disease 
of various etiologies, although multiple echocardiographic abnormalities in 
combination with TR jet performed well with respect to prediction of 
pulmonary hypertension determined at cardiac catheterization. 8 Due to the 
limitations described with estimating PAP by echocardiography, more recent 
investigations have evaluated pulmonary artery acceleration time (PAAT) for 
its accuracy in estimating PAP as well as PVR, as assessed by 
catheterization. 9 PAAT was found to have strong agreement and accuracy 
for the diagnosis of pulmonary hypertension, although again, greater 
discrepancies occurred in actual measures of PAP and PVR when these 
values were more elevated. 9
In this study, our goal is to measure the agreement between the 
echocardiographic assessment of right heart pressure and the pulmonary 
vascular bed, and the presence of elevated PVR on cardiac catheterization in
former preterm infants with BPD, based on multiple quantitative and 
qualitative echocardiographic criteria that are known to reflect either PAP or 
PVR. 
Methods
Subject Enrollment
At UCSF Benioff Children’s Hospital, San Francisco, our practice is to 
screen premature infants with BPD for evidence of pulmonary hypertension 
by serial echocardiograms. If an echocardiogram shows evidence of 
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pulmonary hypertension despite optimization of the patient’s respiratory 
support, the patient undergoes cardiac catheterization prior to starting 
pulmonary vasodilator medications. Pulmonary vasodilator therapy is started
prior to cardiac catheterization only in cases where it is deemed life-saving 
or in patients that are referred from outside institutions already on 
pulmonary vasodilator therapy. Therefore, the population of patients 
undergoing cardiac catheterization would encompass patients with the 
spectrum of mild to severe pulmonary vascular disease. This is a single-
center, retrospective cohort study.  The cardiac catheterization lab database 
was reviewed for preterm infants born < 32wks gestational age who had 
undergone cardiac catheterization between July 2014 and December 2017. 
Patients with congenital heart disease other than atrial septal defect (ASD), 
ventricular septal defect (VSD) and persistent ductus arteriosus (PDA) were 
excluded. Each patient’s electronic medical record was reviewed to identify 
those who have BPD, defined as an oxygen requirement at 36 weeks 
postmenstrual age 10  with an available echocardiogram proximate to the 
cardiac catheterization. Thirty former preterm infants with BPD had 
undergone cardiac catheterization during the study period. One infant was 
excluded because of an inadequate echocardiogram. The cohort consisted of
twenty-nine infants born at a gestational age ≤29 weeks. We collected 
baseline demographics, pulmonary vasodilator therapy and the degree of 
respiratory support at the time of cardiac catheterization by review of the 
medical records.  This study was approved by the University of California San
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Francisco Institutional Review Board.
Echocardiograms
We analyzed the echocardiograms performed closest in time to the 
cardiac catheterizations. In patients who had an intervention (e.g. closure of 
an atrial septal defect (ASD) or a PDA), the echocardiogram performed prior 
to the intervention was analyzed. One investigator (Y.Z.), blinded to the 
results of the cardiac catheterizations, performed all of the 
echocardiographic measurements from stored examinations (online 
supplement: Table 1). All measurements were performed according to the 
American Society of Echocardiography guidelines on quantitative 
assessment in children.11 To include a measurement of the peak velocity of 
the TR jet, two observers (Y.Z. and H.N.) had to agree that the Doppler 
envelope was at least 75% complete with a clear peak and start of 
deceleration. Pulmonary artery acceleration time and right ventricular 
ejection time were measured from a spectral pulse wave Doppler of the right
ventricular outflow tract with clear valve spikes. In addition to measuring the 
right ventricular dimensions, we also collected qualitative assessments of the
right ventricular size and hypertrophy from clinical reports. 
In cases with cardiac shunts, we measured the size of the 
communication, the direction of blood flow and, for VSD or PDA, the systolic 
velocity of blood flow across the shunts. Peak VSD blood flow velocity was 
measured only when the flow occurred during the full duration of systole. An 
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ASD was defined as an inter-atrial communication larger than 3mm. The 
direction of flow in a shunt was determined using a combination of color 
Doppler and spectral Doppler assessments. For patients with a VSD or PDA, 
the systolic PAP was estimated by subtracting or adding (4 x systolic flow 
velocity2) from the systemic blood pressure if the systolic flow direction was 
left to right or right to left, respectively.4,12
Estimation of the peak systolic PAP to systemic blood pressure (SBP) 
ratio (SPAP/SBP) was performed largely by using the RV systolic pressure 
estimate as a proxy for systolic PAP (as there was no RV outflow tract 
obstruction). We used multiple criteria including the peak TR jet velocity, the 
VSD or PDA systolic flow direction and peak velocity and the septal motion. 
The septal motion was graded as no systolic septal flattening (SPAP/SBP < 
0.5), progressive systolic septal flattening (SPAP/SBP 0.5-0.80) and flattened 
septum throughout systole or bulging of the septum into the LV (SPAP/SBP 
>0.8) 13 (Fig. 1) When criteria for assessment of PAP were discrepant, the 
criteria with the highest PAP estimation was used. An echocardiogram was 
considered positive for PVD if:
• TR jet velocity >2.9m/sec14, or
• VSD or PDA systolic flow velocity estimating peak systolic PAP > 
35mmHg, or
• Systolic septal flattening was present
Pulmonary hypertension was graded on echocardiograms as no/mild 
(SPAP/SBP < 0.5), moderate (SPAP/SBP = 0.5-0.8) or severe (SPAP/SBP > 
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0.8) to allow grading of all patients including those with septal position as 
their only sign of pulmonary hypertension. We further analyzed measures of 
right ventricular dimensions, right ventricular systolic function and 
pulmonary flow dynamics to evaluate if additional echocardiographic 
features that correlate with pulmonary vascular resistance increase the 
diagnostic utility of the echocardiographic assessment.
Cardiac catheterizations:
Data collected at the time of cardiac catheterization included infant 
weight and age, indication for catheterization, level of respiratory support, 
type of anesthesia, and detailed hemodynamic data. Measurements of 
pressures were performed using fluid-filled catheters. The average of mean 
pulmonary artery pressure measurements in the right and left pulmonary 
arteries was used for calculations when available. Oxygen saturations and 
partial pressures were measured using blood samples from the different 
cardiac chambers. The dissolved oxygen content of blood was accounted for 
when the partial pressure of oxygen was greater than 100mmHg. Pulmonary 
and systemic blood flows were estimated by the Fick equation, using 
assumed oxygen consumption. 16The transpulmonary gradient was calculated
by subtracting the left atrial pressure from the mean pulmonary artery 
pressure. The left atrial pressure was substituted by the pulmonary artery 
wedge pressure in two patients without an inter-atrial communication. PVR 
was calculated as the transpulmonary vascular pressure gradient divided by 
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the pulmonary blood flow and was indexed to body surface area (PVRi). We 
used two different sets of criteria to define the presence of PVD on cardiac 
catheterization. The first criterion was PVRi ≥3WU only, and the second was 
the updated WHO definition of pulmonary arterial hypertension (developed 
at the 6th World Symposium on Pulmonary Hypertension, Nice 2018), 
requiring PVRi≥3WU, mean PAP ¿20mmHg and pulmonary artery wedge 
pressure ≤15mmHg. 15 We also repeated the analysis using the older WHO 
definition of pulmonary arterial hypertension (PVRi >3WU, mean PAP ≥ 
25mmHg and pulmonary artery wedge pressure ≤15mmHg) 16 as this was 
the standard definition used at the time of these evaluations, to show the 
effect of the updated criterion on the accuracy of echocardiography.
To grade the degree of PAP elevation during cardiac catheterization and 
compare it with degree of elevation of PAP estimated by echocardiography, 
we used two previously described systems to assess PAP elevation  by 
echocardiogram. The first system conformed with published literature of 
assessment of PVD in BPD 3,8 and was defined as: Grade I = SPAP/SBP <0.5, 
Grade II = SPAP/SBP 0.5-0.67 and Grade III = SPAP/SBP >0.67. The second 
system  defined the grades based on previously published criteria to 
estimate PAP from septal position, Grade I SPAP/SBP <0.5, Grade II = 
SPAP/SBP 0.5-0.80 and Grade III = SPAP/SBP >0.80.13 
Statistics
Data are expressed as median values and interquartile range. Nonparametric
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testing was performed due to small sample size. Agreement between a 
positive echocardiogram and a positive cardiac catheterization result for PVD
was quantified by percent agreement. Wilcoxon rank sum test was used to 
assess differences between the groups for continuous variables and Kruskal 
Wallis test was used for ordinal variables. Spearman correlation test were 
used to evaluate the relation between echocardiographic assessment of right
ventricular dimensions, right ventricular function and pulmonary flow 
dynamics, and cardiac catheterization derived PVRi. Since presence of a PDA 
or VSD can change the pulmonary artery pressure and flow dynamics 
irrespective of PVR, we repeated the analysis after excluding patients with 
these shunts. We separately repeated the assessment of right atrial and 
right ventricular dimensions after excluding patients with a hemodynamically
significant ASD defined as an atrial shunt with a Qp:Qs >1.2, determined by 
cardiac catheterization. Statistical analysis was performed using Stata 
(version 13, College Station, TX); differences were considered significant if p 
value < 0.05. 
Results
The indication for cardiac catheterization in twenty five (86%) patients 
was to assess for pulmonary vascular disease, of which 5 patients were also 
suspected to have pulmonary vein stenosis. Three patients underwent 
catheterization for closure of their PDA and one patient for closure of an ASD.
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The baseline demographic characteristics of the cohort are shown in Table 1.
Median duration between the echocardiogram and cardiac catheterization 
was 1 day (IQR; 1,4 days). All infants received the same pulmonary 
vasodilator and vasoactive medication support during both the cardiac 
catheterization and the echocardiogram. Patients on pulmonary vasodilators 
were on a stable regimen prior to both studies except one patient who had a 
9% increase in treprostinil dose between the two studies (from 57ng/kg/min 
to 62ng/kg/min). Only one patient was on other vasoactive medication 
infusions (dopamine and epinephrine), which were at the same doses during 
both studies. Eight patients (36%) had escalation of respiratory support from 
spontaneously breathing during the echocardiogram to positive pressure 
ventilation during cardiac catheterization. No patient had systemic 
hypertension during their echocardiograms.
The measured and calculated hemodynamic data obtained during 
cardiac catheterization are shown in Table 2. Twenty-one patients (72%) had
a PVRi ≥3WU and 20 patients (69%) met the updated WHO definition of 
pulmonary arterial hypertension; one patient had a pulmonary capillary 
wedge pressure of 18mmHg and a PVRi of 5.3WU and so had mixed 
pulmonary arterial and venous hypertension. In contrast, using the older 
WHO definition,  only 15 patients (52%) met criteria for pulmonary arterial 
hypertension. Therefore, 5 patients  reclassified as having pulmonary arterial
hypertension based on the updated definition. These 5 patients had a mean 
PAP range of 21-25mmHg and a PVRi range from 3.2WU  to 6WU. 
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Twenty-five patients (86%) had a positive echocardiogram for PVD 
based on the described criteria. Only six patients (21%) had a measurable TR
jet velocity and in 9 patients (31%) the evaluation was performed solely 
based on the systolic septal motion. Fifty-two percent (15/29) of the cohort 
had either a VSD or a PDA. (Figure 2) 
Using only PVRi to define PVD, patients with a false positive 
echocardiographic assessment (n=6) had measured mean PAP ranging from 
19.5mmHg -40mmHg and PVRi ranging from 1.7WU - 3WU. Five of the six 
patients had a PDA and the sixth had a VSD.  Using the same cutoff value of 
a PVRi >3WU, two patients had a false negative echocardiogram. One had a 
small PDA, with mean PAP of 21mmHg, SPAP/SBP by catheterization = 0.5 
and a PVRi of 4.4WU. The second patient had a TR jet velocity of 2.9m/sec, 
SPAP/SBP = 0.5 by catheterization, mean PAP of 36.5mmHg, and a PVRi of 
4WU. 
After excluding patients with post tricuspid valve shunts (PDA only or 
VSD ± PDA), the agreement between echocardiographic assessment and 
cardiac catheterization derived PVRi > 3 WU x m2 was markedly enhanced 
(Figure 3B and C). Using the PVD definition of PVRi > 3 WU x m2, the 
sensitivity and specificity and accuracy (proportion of infants correctly 
classified) of echocardiography for PVD is shown in Table 3; accuracy was 
enhanced after excluding patients with post tricuspid valve shunts, with 
narrowing confidence intervals despite the smaller number of included 
patients. 
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There was only fair agreement between the echocardiographic 
estimation and the invasively measured grading of the PAP to SBP ratio, 
which was similar regardless of the classification scheme used. (Figure 4)  
Echocardiography demonstrated both under- and over-estimation of the 
systolic PAP to systolic systemic pressure ratio, although inaccuracies by 
echocardiography were no greater than one grade difference from direct 
measurements by cardiac catheterization. 
There were no significant differences between patients with a PVRi ≥3 
and those with a PVR< 3 in any of the echocardiographic variables measured
(Table 4). Of note, patients with mid-systolic notching of the PA Doppler 
pattern had a PVRi range of 8.9WU to 13.1WU. Overall, for patients with any 
shunt by echocardiogram, PVRi was variable, with elevated PVRi in some 
infants with exclusive left-to-right shunts by echocardiography, and normal 
PVRi in two patients with bidirectional flow via PDA (Table 5). 
There were no substantial correlations (rho -0.1 – 0.28) between 
structural or functional echocardiographic assessments and PVRi from 
cardiac catheterization (data not shown). After excluding patients with 
PDA (n=11), there were significant positive correlations between the right 
ventricular myocardial performance index, right ventricular systolic to 
diastolic time index and the ratio of right ventricular to left ventricular 
diameter at end-systole and PVRi, and a trend towards an inverse correlation
between pulmonary artery acceleration time and PVRi (Figure 5A-D). After 
further excluding patients (n=3) with a hemodynamically significant ASD, 
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there was also a trend towards a positive correlation between RV end 
diastolic area and PVRi (Figure 5E). 
Discussion
In this study we found only fair-to-moderate agreement between an 
assessment of elevated PAP using multiple echocardiographic variables and 
classification of pulmonary hypertension from catheter-based calculation of 
PVRi in former preterm infants with BPD. Further, we could not identify any 
substantial correlation between PVRi and multiple echocardiographic 
measurements of right heart and pulmonary vascular structure and function 
except after exclusion of data from patients with post tricuspid valve shunts 
or hemodynamically-significant ASD. We did demonstrate that using the 
updated WHO definition of pulmonary arterial hypertension with a mean PAP 
>20mmHg reflects a PVRi>3WU better than the cut off mean PAP of 
25mmHg used in the prior definition, although utility of echocardiogram 
remained only fair for this study population.  
Mourani and colleagues previously evaluated the clinical utility of 
echocardiography in diagnosing pulmonary hypertension in infants and 
young children with lung disease, including BPD.8 In the current study, the 
duration between cardiac catheterization and echocardiography was shorter,
at a median of 1 day, and as a result, we had consistent pulmonary 
vasodilator therapy during the two studies. Similar to the prior study, we 
utilized multiple echocardiographic measurements to evaluate for elevated 
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PAP, although we allowed for infants to be classified by any of the variables 
that might assess pressure, increasing the proportion of echocardiograms 
that were positive for PVD. In contrast, Mourani et al evaluated single 
abnormal echocardiographic assessments, or concurrent multiple 
echocardiographic abnormalities. Finally, we evaluated utility of 
echocardiography for detection of elevated PVRi, as well as severity 
classification based on pressure measurements alone, whereas the prior 
study used PAP only for the definition of PH. 7,8 Despite these differences, our
findings are similar to the utility of single echocardiographic measurements 
previously demonstrated, with high sensitivity and low specificity for our 
entire cohort. These characteristics are useful for a screening test, but the 
low specificity limits utility as a diagnostic test. 
However, the utility of the screening echocardiogram in this patient 
population is more apparent when infants with post tricuspid valve shunts 
are excluded. Although echocardiography with the exclusion of PDA only still 
has modest specificity (66.7%), the exclusion of echocardiograms with either
PDA or VSD raises specificity to 100% while still demonstrating good 
sensitivity. Post tricuspid valve shunts transmit the systemic pressure to the 
pulmonary circulation regardless of the presence or absence of PVD. 
Therefore, the agreement between echocardiographic assessment of PAP 
and calculated PVRi was markedly improved after excluding patients with 
post-tricuspid valve shunts. It is also important to note that the patients with 
a false negative echocardiographic assessment had truly borderline 
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elevation of PVRi and systolic PAP/SBP ratio. Echocardiography did not miss 
any patients with severe elevation of PVRi. However, echocardiography 
performed poorly when grading the degree of PAP elevation, as was shown in
prior studies. 8
We have identified variables that correlate with the degree of elevation of 
PVRi in patients without post tricuspid valve shunts. These variables may 
have value if studied prospectively in grading the degree of PVD. Namely the
RV MPI, RV SDI, RV-LV diameter ratio at end systole, the direction of flow in 
post tricuspid valve shunts, the shape of the pulmonary artery Doppler signal
and the pulmonary artery acceleration time. These variables have been 
studied, although not exclusively in BPD patients.17-21 Levy et al, in a cohort 
of older children, showed that PAAT correlated well with PVR and proposed a 
cut off PAAT <90msec for prediction of a PVRi >3WU.9 However, in a 
subsequent report by the same author, the PAAT was shortened at age one 
year in all preterm infants born <1000gm regardless of their BPD or prior 
pulmonary hypertension status.22 Our results agree with the author’s first 
report, with higher PVR values associated with shorter pulmonary artery 
acceleration time. Using a cut off value of PAAT < 90msec to diagnose PVD 
in patients without a post tricuspid valve shunt in our cohort, classified 12/14
(86%) patients as correctly having PVD and misclassified only 2 patients (one
with a significant ASD shunt). Future studies should address development of 
cut off values for the aforementioned variables that correlate with the 
presence of PVD or the severity of elevation of PVR.
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Our study has a relatively small sample size, yet is the largest cohort of 
only BPD patients with multiple quantitative measurements applied to the 
whole cohort. However, the small sample size did limit our ability to identify 
statistically significant differences in various echocardiographic variables 
between those infants with PVD versus those without PVD. In particular, we 
are unable to further assess the importance of a notched PA Doppler pattern.
Despite our small cohort, we do demonstrate that purely left to right shunts 
do not exclude pulmonary vascular disease and that bidirectional PDA shunts
do not always imply elevated pulmonary vascular resistance. Further, 
although there is some heterogeneity in our cohort with respect to the 
severity of BPD and baseline pulmonary vasodilator therapy, we present our 
retrospective data in a manner that can be readily applied to any group of 
former preterm infants at risk for PVD: echocardiograms and catheterizations
were performed within a short interval with the same pulmonary vasodilator 
therapy, multiple measurements were used to classify PVD by 
echocardiography, and two different definitions each of both PVD and the 
severity of PH by catheterization were evaluated. The effect of sedation or 
general anesthesia on the correlations between echocardiographic and 
catheterization assessments of pulmonary hemodynamics cannot be 
quantified using our study design. Medications used for sedation during 
cardiac catheterization may have different effects on the systemic and the 
pulmonary circulations. Despite that, similar to other studies of PH in BPD 
patients 3,8, we used the SPAP/SBP ratio to grade the severity of PH mainly 
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because 30% of our cohort only had septal flattening as a sign of PH. 
Conclusion
Echocardiography can be a useful screening tool for PVD in former 
preterm infants with BPD. Utility of echocardiography is limited for the 
presence or severity of PVD, however, when a post tricuspid valve shunt is 
present. Our data suggest that cardiac catheterization remains an important 
diagnostic test to assess severity of both PVD and pulmonary hypertension 
using pressure criteria. Future studies should address the potential value of 
specific echocardiographic measurements for non-invasive assessment of 
calculated PVRi in this population, with consideration of RV myocardial 
performance, end-systolic ventricular dimensions, and PAAT measurements. 
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TABLE 1. Characteristics of the study population (n=29)
Baseline characteristics
Gestational age at birth (weeks and 
days)
25 5/7 (24 4/7 – 26 6/7)
Birth weight (grams) 610 (520-705)
Male sex 17 (59%)
Characteristics at 36 weeks of 
corrected GA
Respiratory support
None 0 (0%)
≤ 2l nasal cannula 2 (7%)
> 2l nasal cannula 5 (17%)
Nasal CPAP or RAM cannula 13 (43%)
Invasive mechanical ventilation 5 (17%)
Unknown 4 (14%)
Oxygen requirement > 30%
Overall 20 (69%)
Of those with ≤ 2l nasal cannula 1 (50%)
Of those with > 2l nasal cannula 3 (60%)
Of those on CPAP or RAM cannula 9 (69%)
Of those on invasive mechanical 
ventilation
5 (100%)
Characteristics of study population at time of cardiac catheter procedure
Postnatal age in days
Postmenstrual age
157 (121-219)
49 0/7 (42 4/7 – 55 6/7)
Weight in grams 3700 (3100-5000)
Medications
Sildenafil 10(33%)
Bosentan 2(7%)
Prostanoid
iNO
Respiratory support
2(7%)
4(13%)
None 1 (3%)
Nasal cannula ≤ 2lpm
FiO2 
7 (24%)
1.0 (0.4-1.0)
Nasal cannula > 2 lpm
FiO2
4 (14%)
0.4 (0.3-0.5)
Nasal CPAP or RAM cannula
FiO2
10 (35%)
0.4 (0.3-0.5)
Conventional mechanical ventilation
FiO2
7 (24%)
0.5 (0.4-0.9)
Anesthesia for procedure for infants 
with natural airway (n= 22)
Spontaneously breathing 14 (64%)
Positive pressure ventilation 8 (36%)
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Continuous variables are shown as median and interquartile range, dichotomous or 
categorical variables as n and proportions (%)
TABLE 2. Hemodynamic variables obtained by cardiac catheterization
Variables (N=29) Median (Q1, Q3)
Right atrial mean pressure
(mmHg)
7 (6,8)
Left atrial mean pressure
(mmHg)
9 (7,10)
Systolic PAP (mmHg) 47 (39,54.5)
Mean PAP (mmHg) 32 (25,39.5)
Diastolic PAP (mmHg) 18.8 (13, 24)
Systolic PAP/SBP ratio 0.58 (0.52,0.74)
PVRi (WU) 4.6 (3,6.6)
PVRi/SVRi 0.31 (0.22,0.58)
Qp (mL/min/m2) 4.25 (3.2,5.6)
Qp:Qs 1.1 (1,1.6)
PAP = pulmonary artery systolic pressure, PVRi= pulmonary vascular 
resistance indexed to body surface area, Qp = pulmonary blood flow, Qs = 
systemic blood flow, SBP = systolic systemic blood pressure, SVRi = 
systemic vascular resistance indexed to body surface area  
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TABLE 3. Accuracy, sensitivity and specificity of echocardiography in 
diagnosing pulmonary vascular disease by cardiac catheterization.
Accura
cy
Sensitiv
ity
Specific
ity AUC (CI)
Prior WHO Definition: PVRi ≥ 3WU, mean PAP ≥ 25mmHg, PCWP ≤
15mmHg
Positive echocardiogram
for PH (n=29) 57 56 75
0.65 (0.39-
0.92)
Updated WHO Definition*: PVRi ≥ 3WU, mean PAP > 20mmHg, PCWP
≤ 15mmHg
Positive echocardiogram
for PH (n=29) 69 72 50
0.61 (0.31-
0.9)
PVRi ≥ 3WU
Positive echocardiogram
for PH (n=29) 72 90.5 25
0.58 (0.39–
0.76)
Septal position (n=29) 69 85.7 25 0.61 (0.42-0.79)
Positive echocardiogram
for PH excluding patients
with PDA (n=18)
89 93.3 66.7 0.8 (0.52-0.94)
Septal position excluding
patients with PDA (n=18) 83 86.7 66.7
0.8 (0.52-
0.94)
Positive echocardiogram
for PH excluding patients
with PDA & VSD (n=14)
93 91.7 100 0.96 (0.66-0.99)
Septal position excluding
patients with PDA & VSD
(n=14)
93 91.7 100 0.96 (0.66-0.99)
*WHO definition updated following the study period, at the 6th World 
Symposium on Pulmonary Hypertension, Nice 2018
AUC = area under the curve, CI = confidence interval, PAP = pulmonary 
artery pressure, PCWP = pulmonary capillary wedge pressure, PH = 
pulmonary hypertension, PVRi= pulmonary vascular resistance indexed to 
body surface area 
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TABLE 4. Echocardiographic variables in patients with and without 
pulmonary vascular disease based on a cutoff PVRi of 3 WU
PVRi ≥3
(n=21)*
PVRi ≤ 3
(n=8)*
P 
value
Quantitative Dimensions                    
RA Area (cm2) 2.7 (2.3-4.4) 3.3 (3-3.7) 0.33
RA Area indexed (cm2/m2) 13.1 (12.3-15.5) 14.1 (13.7-14.8) 0.31
RV basal diameter (cm) 16.1 (15.7-18.1) 19 (15.7-21.3) 0.07
RV mid diameter (cm) 12.8 (11.8 – 15.1) 14.4 (11.9 – 16.7) 0.31
RV area end diastole (cm2) 3.3 (3 – 4.2) 4.4 (3.3 - 5) 0.17
RV area end diastole (Z 
score >2)
4.7% (1/21) 37% (3/8)  0.05
RV area end systole (cm2) 2 (1.7 – 2.7) 2.4 (2 – 3.2) 0.34
RV:LV end systolic diameter
ratio
1.1 (0.9 - 1.34) 1.2 (1.16 - 1.42) 0.44
RVOT diameter (cm) 0.9 (0.8 – 1) 0.9 (0.8 - 1) 0.49
Main PA diameter (cm) 1 (0.9 – 1.2) 1 (1.1 – 1.2) 0.79
Right PA diameter (cm) 0.5 (0.5 - 0.7) 0.5 (0.6 - 0.7) 0.54
Left PA diameter (cm) 0.5 (0.4 - 0.6) 0.5 (0.5 - 0.7) 0.56
Qualitative Dimensions                      
RV Hypertrophy     0.73
      no 33% (7/21) 37.5% (3/8)  
      mild 62% (13/21) 62.5% (5/8)  
      moderate 5% (1/21)  0  
RV dilation     0.57
      no 19% (4/21) 12.5% (1/8)  
      mild 47.5% (10/21) 37.5% (3/8)  
      moderate 24% (5/21) 50% (4/8)  
      severe 9.5% (2/21) 0  
Function                                              
TAPSE (cm) 1 (0.8 – 1.3) 1.1 (0.9 – 1.2) 0.7
TAPSE z score -1 (-1.7 – 1.1) 1.8 (-1.2 – 3.4) 0.21
RV FAC (%) 38 (36 – 40) 39 (38 – 43) 0.38
RV SDI (blood pool) 1.9 (1.6 – 2.1)
(n=17)
1.8 (1.6 – 1.9)
(n=5)
0.32
RV SDI (TDI) 1.9 (1.6 – 2)
(n=15)
1.8 (1.2 – 2.1)
(n=6)
0.53
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RV s’ TDI (cm/sec) 8.3 (7.7 – 10.7)
(n=15)
8.3 (8 – 10)
(n=6)
0.97
RV MPI 0.32 (0.26 – 0.38)
(n=14)
0.24 (0.19-0.42)
(n=4)
0.34
RV CO indexed (L/min/m2) 4.3 (2.9 – 6.3)
(n=19)
4.2 (2.7 - 6) 0.96
Pulmonary flow dynamics               
PAAT (msec) 53 (45 – 82)
(n=19)
89 (43 – 105) 0.31
PAAT/RVET 0.28 (0.25 – 0.43)
(n=19)
0.44 (0.24 – 0.54) 0.3
PA Doppler pattern  Normal     37% 
(7/19)
 Normal    62.5% 
(5/8) 
 0.14
Triangle     42% 
(8/19)
Triangle    37.5% 
(3/8)
Notched      21% 
(4/19)
Notched    0
Data are median (IQR) or percentage
*unless otherwise noted
CO = cardiac output, FAC = fractional area change, LV= left ventricle, MPI = 
myocardial performance index, PA = pulmonary artery, PAAT= pulmonary 
artery acceleration time, RA = right atrium, RV = right ventricle, RVOT = 
right ventricular outflow tract, SDI = systolic to diastolic time index, TAPSE =
tricuspid annular plane excursion, TDI = tissue Doppler imaging
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Table 5. PVRi values grouped by shunt flow direction
Shunt Direction of flow (N) P value
                                PVRi median (Q1,Q2)
Inter-atrial
communication
L to  R 
(n=22)
Bidirectiona
l
 (n=5)
R to   L 
(n=1)
0.14
4.5 (2.8,6) 5.8
(4.2,10.1)
13.1
PDA
L to  R 
(n=8)
Bidirectiona
l 
(n=2)
R to   L 
(n=1)
0.18
4.3
(2.5,5.5)
1.7 /3 8.9
VSD 
L to  R 
(n=3)
Bidirectiona
l 
(n=1)
R to   L 
(n=1)
0.2
2.8-4.6 12.6 8.9
L to R = left to right, PVRi= pulmonary vascular resistance indexed to body 
surface area, R to L = right to left 
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Figure 1. Parasternal short axis images of three different septal 
positions at end systole depicting the different grades of pulmonary
hypertension.
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Figure 2. Flow chart of echocardiographic screening and cardiac 
catheterization results based on presence or absence of a PDA or VSD 
29 former 
preterm infants 
with BPD
14 
No PDA or VSD
15 
PDA or VSD
3 negative screen
11 positive screen
- 3 positive TR jet
- 11 positive septal 
motion
1 negative screen
14 positive screen
- 12 septal motion
- 9 PDA gradient
- 4 VSD gradient
9 PVD
6 No PVD
12 PVD
2 No PVD
PDA or VSD Echocardiogram Cardiac Catheterization
PVD = PVRi ≥ 3 WUPositive echocardiographic screen =
- TR jet velocity >2.9m/sec
OR 
- VSD or PDA systolic flow velocity 
estimating peak systolic PAP > 35mmHg
OR 
- Systolic septal flattening was present
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Figure 3. Agreement between echocardiographic estimation of elevated 
pulmonary artery pressure and cardiac catheterization derived PVRi ≥ 3 WU 
x m2 in A) all cohort B) cohort after excluding patients with PDA C) cohort 
after exclusion all patients with post tricuspid valve shunts.
 
PVRi= pulmonary vascular resistance indexed to body surface area
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Figure 4. Bar graph showing poor agreement between echocardiographic 
and cardiac catheterization grading of pulmonary artery pressure using two 
different classification systems A) classification from published literature in 
infants with bronchopulmonary dysplasia, B) classification from septal 
motion literature. There is over estimation and under estimation of no/mild 
and severe pulmonary hypertension respectively. There is both under and 
over estimation of moderate pulmonary hypertension.
 
  
SPAP/SBP = ratio of systolic pulmonary artery pressure to systemic systolic 
blood pressure
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Figure 5. Correlation between PVRi and A) RV MPI, B) RV SDI by TDI, C) 
RV/LV diameter ratio at end systole, D) PAAT, in the absence of a PDA. E) 
Correlation between RV end diastolic area and PVRi in the absence of PDA 
and a hemodynamically significant ASD.
Individual observations are plotted. Verticle lines represent PVRi = 3WU.
PAAT = pulmonary artery acceleration time, PVRi = pulmonary vascular 
resistance indexed to body surface area, RV/LV diameter ratio = right 
ventricular to left ventricular diameter ratio at end systole, RV MPI = right 
ventricular myocardial performance index, RV SDI TDI = right ventricular 
systolic to diastolic time index measured by tissue Doppler imaging
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Online supplement
TABLE 1. Two-dimensional, blood pool and tissue Doppler variables 
collected in the study.
Two Dimensional measurements:
 Right atrial area at end systole from apical 4 chamber view (cm2)
 Right ventricular basal diameter at end diastole from apical 4 
chamber view (cm)
 Right ventricular mid-cavity diameter at end diastole from apical 4 
chamber view (cm)
 Right ventricular outflow tract diameter from short axis view of the 
cardiac base (cm)
 Right ventricular diameter at end systole from short axis view at the 
papillary muscle level. (cm)
 Right ventricular area at end diastole from apical 4 chamber view 
(cm2)
 Right ventricular area at end systole from apical 4 chamber view 
(cm2)
 Tricuspid annular plane systolic excursion (cm)
 Main and branch pulmonary artery diameters from short axis of the 
cardiac base (cm)
 Left ventricular diameter at end systole from short axis at the 
papillary muscle level. (cm)
Blood pool Doppler measurements
 Tricuspid regurgitation jet peak velocity (m/sec)
 Tricuspid valve inflow duration (msec)
 Blood pool cycle length (msec)
 Pulmonary artery acceleration time (PAAT) (msec)
 Right ventricular ejection time (RVET) (msec)
 Right ventricular ejection velocity time integral (RV VTI) (cm)
 Peak systolic velocity of flow across PDA or VSD (m/sec)
Tissue Doppler measurements
 Lateral tricuspid valve annular peak systolic (s’) velocity (m/sec)
 Lateral tricuspid valve annular filling time duration
 Tissue Doppler cycle length (msec)
Calculations
 To convert velocity to pressure gradients, a simplified Bernoulli 
equation was used Pressure gradient = 4 x velocity2
 Right ventricular fractional area change (RV FAC): (right ventricular 
area at end diastole – right ventricular area at end systole) / right 
ventricular area at end diastole
 Pulmonary blood flow = ( x (RVOT diameter/2)2 x RV VTI) x heart 
rate
 PAAT corrected to heart rate = PAAT/RVET
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 Systolic to diastolic time index: (cycle length – filling time)/filling time
Qualitative assessment
 Right ventricular dilation
 Right ventricular hypertrophy
 Septal motion
 Pulmonary artery Doppler pattern (normal / triangular / mid-systolic 
notch)
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